CEBPA and acute myeloid leukemia: Optimization of prognostic evaluation and treatment choice for AML patients with CEBPA mutations by MRD status during treatment here may suggest that an integrated prognostic system should be established with both pre-treatment (cytogenetic and genetic alterations) and post-treatment (MRD status) parameters, in order to direct choosing treatment strategies post remission.